LOGIN  |  REGISTER
Surmodics
Astria Therapeutics

Encompass Health to present at 2024 Leerink Partners Healthcare Crossroads Conference

May 23, 2024 | Last Trade: US$85.25 0.79 -0.92

BIRMINGHAM, Ala., May 23, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the 2024 Leerink Partners Healthcare Crossroads Conference being held in Austin, Texas, May 28-30, 2024.

Encompass Health's President and Chief Executive Officer Mark Tarr and Executive Vice President and Chief Financial Officer Doug Coltharp will present during a fireside chat on Thursday, May 30, 2024, from 8-8:30 a.m. CT.

The presentation will be webcast live and available at http://investor.encompasshealth.com.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 162 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Media Contact
Polly Manuel | 205 970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations Contact
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Astria Therapeutics

Stock Quote

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB